Ovid Therapeutics Inc.
OVID
$2.42
$0.062.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 443.94% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 443.94% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | 443.94% | |||
| SG&A Expenses | 3.78% | -5.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 37.16% | 2.81% | |||
| Operating Income | -45.17% | 1.84% | |||
| Income Before Tax | -275.80% | 179.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -275.80% | 179.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -275.80% | 179.48% | |||
| EBIT | -45.17% | 1.84% | |||
| EBITDA | -45.09% | 1.85% | |||
| EPS Basic | -202.63% | 171.11% | |||
| Normalized Basic EPS | 10.55% | 18.43% | |||
| EPS Diluted | -202.63% | 171.11% | |||
| Normalized Diluted EPS | 10.55% | 18.43% | |||
| Average Basic Shares Outstanding | 66.73% | 14.85% | |||
| Average Diluted Shares Outstanding | 66.73% | 14.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||